RxDoctor Payments DataLook up a doctor →

Costantine Albany, MD

Medical Oncology · Lafayette, INNPI 1427381607

Payments from drug & device makers

$1,088,921in general payments, 2019–2025

Across 408 payments — averaging $2668.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$540K
  • Otsuka Pharmaceutical Co., Ltd.$150K
  • Seagen Inc.$148K
  • Sanofi$98K
  • Bayer$44K
  • Veloxis Pharmaceuticals, Inc.$41K
  • plus $68K from 48 others

What the payments were for

  • Consulting fees$12,7986%
  • Speaking & faculty fees$162,81477%
  • Travel & lodging$27,95413%
  • Food & beverage$8,1464%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,088,921 in reported general payments places this provider in the 90th percentile of 67 medical oncology providers in Indiana.

See all medical oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$750,981
Medicare patients
510
Services billed
24,473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate30$460,141
JakafiRuxolitinib Phosphate21$418,486
Lenalidomide24$339,286
PomalystPomalidomide13$270,826
TasignaNilotinib Hcl13$262,682
IbrancePalbociclib21$260,534
TagrissoOsimertinib Mesylate13$241,246
TafinlarDabrafenib Mesylate12$173,133
EliquisApixaban108$75,752
XareltoRivaroxaban59$45,993
Abiraterone Acetate25$26,670
Enoxaparin Sodium15$8,749
Exemestane13$1,999
Letrozole44$1,073
Potassium Chloride44$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Tagrisso$33,244$701,38643 claims
NovartisTasigna, Tafinlar$155$435,81525 claims
Incyte CorporationJakafi$146$418,48621 claims
PfizerIbrance, Eliquis$159$336,286129 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$181$270,82613 claims
Johnson & JohnsonXarelto$228$45,99359 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$50$26,67025 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$14$55440 claims
Lilly USA, LLCOlanzapine$59$42513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 67 medical oncology providers in Indiana.

Other medical oncology in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →